S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

Home
Investing
Stocks
USA
NASDAQ
HUTCHMED China Limited (HCM)
HUTCHMED China Limited (HCM) News

HCM

HUTCHMED China (HCM)

HUTCHMED China Limited

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:HCM

1 2 3 4 5 6 7 8 9 10 Next >>

Date	Time	Source	Headline	Symbol	Company
05/08/2024	3:30AM	GlobeNewswire Inc.	HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee	NASDAQ:HCM	HUTCHMED China Limited
04/26/2024	7:30AM	GlobeNewswire Inc.	HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda	NASDAQ:HCM	HUTCHMED China Limited
04/05/2024	3:30AM	GlobeNewswire Inc.	HUTCHMED Highlights Data to be Presented at AACR Congress 2024	NASDAQ:HCM	HUTCHMED China Limited
04/01/2024	11:30PM	GlobeNewswire Inc.	HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status	NASDAQ:HCM	HUTCHMED China Limited
03/27/2024	7:00PM	GlobeNewswire Inc.	HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC	NASDAQ:HCM	HUTCHMED China Limited
03/21/2024	7:00PM	GlobeNewswire Inc.	HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China	NASDAQ:HCM	HUTCHMED China Limited
03/05/2024	5:04AM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
02/28/2024	5:47AM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
02/28/2024	5:40AM	Edgar (US Regulatory)	Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]	NASDAQ:HCM	HUTCHMED China Limited
02/28/2024	5:30AM	GlobeNewswire Inc.	HUTCHMED Reports 2023 Full Year Results and Provides Business Updates	NASDAQ:HCM	HUTCHMED China Limited
02/07/2024	5:43AM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
02/06/2024	6:00PM	GlobeNewswire Inc.	HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session	NASDAQ:HCM	HUTCHMED China Limited
02/02/2024	5:15AM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
02/02/2024	2:30AM	GlobeNewswire Inc.	HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership	NASDAQ:HCM	HUTCHMED China Limited
02/01/2024	5:06AM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
02/01/2024	2:30AM	GlobeNewswire Inc.	HUTCHMED to Announce 2023 Final Results	NASDAQ:HCM	HUTCHMED China Limited
01/30/2024	5:17AM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
01/29/2024	10:53PM	GlobeNewswire Inc.	HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer	NASDAQ:HCM	HUTCHMED China Limited
01/11/2024	5:02AM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
01/10/2024	6:00PM	GlobeNewswire Inc.	HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status	NASDAQ:HCM	HUTCHMED China Limited
12/29/2023	5:04AM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
12/21/2023	5:14AM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
12/13/2023	5:04AM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
12/12/2023	10:30PM	GlobeNewswire Inc.	HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms	NASDAQ:HCM	HUTCHMED China Limited
12/12/2023	6:00PM	GlobeNewswire Inc.	HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China	NASDAQ:HCM	HUTCHMED China Limited
12/07/2023	5:03AM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
12/01/2023	5:03AM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
11/30/2023	6:00PM	GlobeNewswire Inc.	HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses	NASDAQ:HCM	HUTCHMED China Limited
11/30/2023	5:09AM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
11/10/2023	7:35AM	GlobeNewswire Inc.	Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing	NASDAQ:HCM	HUTCHMED China Limited

Showing the most relevant articles for your search:NASDAQ:HCM

1 2 3 4 5 6 7 8 9 10 Next >>

TransCode Therapeutics

Federal Home Loan Mortgage (QB)

Ecare Solutions (PK)

ProText Mobility (PK)

Voip Pal Com (QB)

Northwest Biotherapeutics (QB)

Net Savings Link (PK)

TPT Global Tech (CE)

Ronn Motor (PK)

Bioelectronics (PK)

Fannie Mae (QB)

Good Vibrations Shoes (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions